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Interest in probiotic research and its potential benefits in infant foods are relatively recent 
but significantly increasing. The evolution of the knowledge in the last 20 years demon-
strated that alterations in the microbiome may be a consequence of events occurring 
during infancy or childhood, including prematurity, cesarean section, and nosocomial 
infections. Several pieces of evidence prove that a “healthy” intestinal microbiota facili-
tates the development of immune tolerance. Interventional studies suggest that probiot-
ics could be protective against the development of many diseases. Nevertheless, many 
factors complicate the analysis of dysbiosis in subjects with food allergy. Comparison 
in-between studies are difficult, because of considerable heterogeneity in study design, 
sample size, age at fecal collection, methods of analysis of gut microbiome, and geo-
graphic location. Currently, there is no positive recommendation from scientific societies 
to use pre- or probiotics for treatment of food allergy or other allergic manifestations, 
while their use in prevention is being custom-cleared. However, the recommendation is 
still based on little evidence. Although there is valid scientific evidence in vitro, there is 
no sufficient information to suggest the use of specific probiotics in allergy and asthma 
prevention.
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inTRODUCTiOn
The 2001 FAO/WHO definition of probiotics (“live microorganisms that, when administered in 
adequate amounts, confer a health benefit on the host”) has been widely adopted by regulatory agen-
cies, such as Codex alimentarius, the European Food Safety Authority (EFSA), scientists, industry, 
and consumers. Everyone agrees that a specific probiotic strain should have been investigated in 
properly controlled studies to confer a specific benefit before claiming the existence of such benefit. 
If this is not fulfilled, the only allowed claim would be “contains probiotics.” Studies using probiotics 
or prebiotics have been generally designed as exploratory and were not sufficiently designed to fulfill 
the criteria for substantiation of a health claim under the current regulation by EFSA (1).
In order to recommend specific probiotics or a mixture of probiotic strains for allergy prevention, 
they must prove to reduce the risk of later allergies when given to the pregnant or breast-feeding 
mother or directly to the infant.
Interest in probiotic research and its potential benefits in infant foods is quite recent, but sig-
nificantly increasing. According to a recent bibliometric analysis, the total number of documents 
published on probiotics in pediatrics over the period 1994–2014 was 2817. Research production 
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on probiotics in pediatrics showed a 90-fold increase during the 
study period. Approximately 22% of articles originated from USA 
and has the greatest share (2). The top 10 cited articles over the 
past two decades revealed that the majority of most important 
articles focused on the role of probiotics in the treatment of 
allergy and diarrhea in children. In Table 1, we summarize the 
main mechanisms of action of probiotics.
PRObiOTiCS in PeDiATRiCS
In the last 20 years, it became clear that events occurring dur-
ing infancy or childhood, including prematurity, cesarean 
section, and infections, influence the microbiome. Microbiome 
alterations have been associated with infantile colic, necrotizing 
enterocolitis, asthma, atopic diseases, diabetes, mood disorders, 
and autism spectrum disorders (3).
Interventional studies suggest that probiotics could prevent or 
reduce the severity of some of these diseases, but the biological 
mechanisms—and the optimal intervention for each—remain 
poorly understood.
PRObiOTiCS FOR AlleRGY PRevenTiOn
A “healthy” intestinal microbiota facilitates the development of 
immune tolerance (4, 5). Earlier studies showed that gut-associated 
lymphoid tissues (GALT), including Peyer’s patches, are poorly 
developed or absent in germ-free mice (6, 7). It was shown that 
the introduction of Bacteroides fragilis into the lower gut of germ-
free mice in the neonatal period could lead to a redevelopment of 
GALT and induction of tolerance (8). It was also proven that the 
inability to establish an effective immune tolerance early in life 
increases the host’s risk of developing allergic and inflammatory 
diseases (9). For example, mice raised in a sterile environment 
show reduced immunoglobulin A and interleukin (IL)-10 pro-
ducing T  regulatory (Treg) cells and are unable to develop oral 
antigenic tolerance (7, 10, 11). Segmented filamentous bacteria 
and Clostridium species, particularly clusters IV and XIVa, pro-
mote the development of IL-17-producing T cells and Treg cells, 
respectively (12, 13). Furthermore, the gut microbiota of food 
allergic mice—but not of tolerant ones—transmitted susceptibil-
ity to food allergy when transferred into germ-free mice (14).
Many factors complicate the analysis of dysbiosis in subjects 
with food allergy. Comparisons between studies are difficult, 
because of heterogeneity in study design, sample size, age at fecal 
collection, methods of analysis of gut microbiome, and geo-
graphic location (15). Nevertheless, evidence of gut dysbiosis in 
food allergy is evolving with time, aided by increasing availability 
of new techniques. Studies relying on bacterial cultures showed 
that infants allergic to cow’s milk had higher total bacteria and 
anaerobic counts (16), but this finding was not consistent across 
studies (17) and no association could be established between 
culturable gut bacteria and sensitization to food, including milk, 
casein, egg, peanut, and hazelnut (18).
The hypothesized mechanisms by which the commensal 
microbiota influences the outcome of the allergic response are 
manifold (19). Intestinal bacteria can modulate the innate lym-
phoid cells, directly acting on Tregs through their toll-like receptors 
(TLRs). Commensal microbiota promotes the differentiation of 
induced Tregs (iTreg) from naïve CD4+ T-cells by a Treg intrinsic, 
TLR- and myeloid differentiation primary response gene 88 
(MyD88)-dependent mechanism (20, 21).
Another mechanism by which the commensal flora promotes 
tolerance is the production of short chain fatty acids (SCFAs), 
generated by bacterial fermentation of dietary fibers. SCFA act 
on T cells via a G-protein-coupled receptor (GPR43) and protect 
mice from intestinal inflammation by expanding colonic Treg cells 
(22). SCFAs also promote the generation of intestinal Treg cells 
from naïve CD4+ T cells by T-cell intrinsic epigenetic mechanisms 
(23). Butyrate, a SCFA known as histone deacetylase inhibitor, 
increases Foxp3 protein acetylation conferring increased stability 
and enhanced suppressive function on de novo generated intesti-
nal iTreg cells (24). A high fiber diet protects against allergic airway 
inflammation by altering the composition of the flora, leading to 
increased Bacteroidetes and decreased Firmicutes, and resulting 
in increased circulating levels of SCFAs (25).
PRObiOTiCS FOR PRevenTiOn OF 
ASTHMA AnD eCZeMA
In general, preventive strategies for asthma and allergic disorders 
have been proposed in 2014 (26):
 (1) General health education: avoidance of tobacco smoke expo-
sure during pregnancy and after birth.
 (2) Primary prevention for infants at higher risk. Several lon-
gitudinal birth cohort studies have clearly demonstrated an 
increased risk of allergic manifestations if one or two parents 
are or have been affected themselves.
 (3) Secondary prevention strategies for children who have 
already developed allergic sensitization or the first manifesta-
tions of allergic diseases; those strategies aim to reduce the 
incidence of clinical manifestations, such as rhinitis, food 
allergy, or asthma.
Pre-clinical studies have shown that modifying the microbiota 
could modulate the global immune response of the host, thus 
reducing sensitization and allergic inflammation (7, 11). Many 
studies have suggested the hypothesis that pre- and probiotics 
might be protective for asthma.
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The inhalation of allergens stimulates the innate immune 
system to release cytokines which promote antigen expressions 
on CD4+ T-cells and activate the antigen-presenting cells and the 
T cells to produce Th2 responses (27, 28). Th2 cytokines (IL-4, 
IL-5, IL-9, and IL-13) induce asthma-like changes in the airways 
and lung parenchyma, as airway eosinophilia, pulmonary lym-
phocytosis, mastocytosis, alternative macrophage activation, and 
epithelial cell proliferation with goblet cell hyperplasia. Previous 
studies have shown that matrix metalloproteinases, members of 
a family of enzymes that cleave extracellular matrix proteins, are 
implicated in many inflammatory conditions (29). Specifically, in 
asthma, MMP9 levels are significantly increased (30). Treatment 
with LGG has been shown to decrease MMP9 expression in 
lung tissue and to inhibit inflammatory cell infiltration. In addi-
tion, in OVA-sensitized mice, LGG reduced OVA-specific IgE 
levels in serum, suppressed the airway hyper-responsiveness to 
methacholine and decreased the number of infiltrating inflam-
matory cells and Th2 cytokines in bronchoalveolar lavage fluid 
and serum (31). Similar results have been reported with other 
probiotics (32).
Specifically, in pediatric asthma, LGG was reported to reduce 
the concentration of exhaled nitric oxide among 4- to 7-year-olds 
(33), but these results could not be replicated (34).
Early administration of Lactobacillus reuteri to infants did 
not result in a reduction of asthma [RR 1.16 (0.33–4.10)], nor 
did Lactobacillus rhamnosus HN001 [RR 0.95 (0.62–145)] or 
Lactobacillus paracasei spp. paracasei F19 [RR 1.05 (0.39-2.81)] 
(35–37).
Better results have been obtained with probiotic bacteria based 
on in vitro modulation of cytokine production. Bifidobacterium 
bifidum, B. lactis, and Lc. lactis were shown to have a good 
IL-10-inducing capacity and to exert a significant inhibition of 
Th2-related cytokines IL-5 and IL-13 (38–40). Administered 
perinatally in a selected combination, they reduced the develop-
ment of eczema up to the age of 2 years. Their beneficial effect 
does not reach the age of 6 years and does not lead to primary 
prevention of asthma.
A systematic review of randomized trials assessing the 
effects of any probiotic administered to pregnant women, 
breast-feeding mothers, or infants demonstrated that probiotics 
could reduce the risk of eczema in infants (41). The certainty 
in the evidence is low or very low because of the risk of bias, 
inconsistency and imprecision of results, and indirectness of 
available research.
As underlined in two recent reviews, replication of the 
promising results in collaborative well-coordinated multicen-
tre harmonized studies with multidisciplinary expertise in 
pediatrics, immunology, and microbiology would, thus, be of 
great importance to enable future evidence-based implementa-
tion (42).
A more prolonged gut microbiota management could achieve 
a long-lasting impact (43, 44).
GUiDelineS ReCOMMenDATiOnS: OveR 
TO SCienTiFiC SOCieTieS
 – The European Academy of Allergy and Clinical Immunology 
(EAACI) stated in its food allergy and anaphylaxis guidelines 
on primary prevention of allergy, that “there is no evidence to 
recommend prebiotics or probiotics or other dietary supple-
ments based on particular nutrients to prevent food allergy” 
in at risk groups and in the general population (grade of 
recommendation B) (45).
 – The Nutrition Committee of the European Society of 
Paediatric Gastroenterology, Hepatology and Nutrition 
(ESPGHAN) concluded 2011 after a systematic literature 
review on the effect of infant formula supplemented with 
prebiotics or probiotics on the preventive effect on allergy, 
that “there is too much uncertainty to draw reliable conclu-
sions from the available data” (46).
 – The World Allergy Organization (WAO) suggested 2015 on 
their guidelines on the prevention of allergy to consider using 
probiotics in:
 (a) women pregnant with children with high risk for allergy,
 (b) women who breastfeed infants at high risk of developing 
allergy, and
 (c) infants at risk of developing allergies, because there is a net 
benefit resulting in primary prevention of eczema (47).
COnClUSiOn
There is no positive recommendation from any scientific com-
munity to use specific probiotics for the prevention of food 
allergy or other allergic manifestations (48), but their use in 
prevention as a whole class has widespread in clinical practice 
(49, 50). We are more open to the use of probiotics than in 
the past, but the recommendation is based on little evidence. 
Although there is valid scientific evidence in vitro, there is no 
sufficient information to suggest that the use of probiotics is 
effective in preventing allergy and asthma. At this point, it seems 
necessary to understand more precisely the microbiota composi-
tion of healthy humans. Only by identifying the specific changes, 
we would realize that the “ideal probiotic,” able to prevent or 
fight specific dysbiosis of specific disease. Future studies will 
take stock of state-of-the-art methods for the evaluation of the 
microflora to better define the indications, the probiotic strains, 
and the type of prebiotic used.
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